New Jersey’s Attorney General and Division of Consumer Affairs alerted the public that three synthetic kratom-related compounds became illegal to possess or sell in the state under a temporary federal scheduling order. The release describes a controlled-substance alert, not a privacy enforcement action, and identifies no company, privacy violation, or monetary penalty.
No privacy-related remedy or monetary penalty is described. The alert states that the listed compounds are scheduled as illegal to possess or sell in New Jersey, with potential criminal charges for violations.
This release does not describe a privacy enforcement action, so it does not indicate a need to revise privacy or data-processing clauses. Product, procurement, and legal teams dealing in kratom-related products should review supplier and distribution agreements for representations that products and ingredients comply with applicable controlled-substance laws, ingredient and labeling disclosure obligations, prompt notice of regulatory changes, audit or documentation rights, and rights to suspend sales or terminate if an ingredient becomes restricted. Customer-facing terms may also need review for accurate product descriptions and restrictions on sale or possession.
Entity
Mitragynine pseudoindoxyl, MGM-15, and MGM-16
Industry
OtherOfficial Press Release
https://www.njoag.gov/ag-davenport-division-of-consumer-affairs-issue-public-alert-three-types-of-synthetic-kratom-to-be-listed-as-controlled-dangerous-substances-in-new-jersey/
New Jersey Attorney General Enforcement Page
https://www.njoag.gov/about/divisions-and-offices/division-of-consumer-affairs/
"mitragynine pseudoindoxyl, MGM-15, and MGM-16"
"Under New Jersey law, if the federal government schedules a drug and the Director of the Division of Consumer Affairs does not object–which he did not in this case– that drug automatically becomes scheduled in New Jersey too."
"In August 2026, the U.S. Drug Enforcement Administration (DEA) temporarily classified three synthetic compounds related to synthetic kratom–mitragynine pseudoindoxyl, MGM-15, and MGM-16–as Schedule I drugs."
"Starting Today, Anyone Possessing or Selling These Products Could Face Criminal Charges"
"For Immediate Release: September 25, 2026"
$10.0M
A March 2023 breach at the Perry Johnson companies exposed personal and protected health information belonging to more than 13.3 million people. The companies agreed to pay at least $300,000 in penalties, with an additional $9.7 million payable if they fail to meet the agreement, and to implement security, incident-response, and data-handling reforms.
$220.0M
A 36-attorney-general coalition resolved allegations that General Motors collected and sold identifiable driver behavior and location data to data brokers, which supplied it to insurers for use in assessing drivers and potentially raising premiums. The $220 million nationwide settlement requires affirmative express consent before collecting or disclosing driving and location data, limits data collection, and imposes privacy-program assessments and dealership oversight and training.
New Jersey, the FTC, and a coalition of 19 other states sued Dollar General, alleging that customers were repeatedly charged more at checkout than prices displayed on shelves, tags, and advertisements. The complaint alleges deceptive pricing practices and inadequate safeguards despite consumer complaints; the release does not describe a settlement, penalty, or other remedy imposed.
New Jersey joined a coalition of state attorneys general in filing a notice in Character Technologies, Inc.’s bankruptcy proceedings, raising concerns about the company’s safety and privacy practices and the sensitive conversations it holds, including those involving children and mental health. The states seek safeguards for consumers’ personal information in any sale or transfer of the company’s business or assets; the release does not report a fine or final finding of violations.
A multistate coalition co-led by New Jersey won a federal court order rejecting the Trump Administration’s decision not to request funding for the CFPB. The order struck down that decision and directed the Administration to follow the law and fund the agency; no monetary penalty or privacy violation is described.
$2.3M
Laboratory Corporation of America Holdings agreed to pay $2,287,455 to participating states and strengthen its security and vendor-management practices following an investigation into the 2019 breach at its debt-collection vendor, AMCA. The breach potentially exposed information of more than 27.5 million people nationwide, including sensitive information belonging to approximately 10.2 million LabCorp patients.